PWN4PWN Newsroom
Welcome to the PWN4PWN Newsroom — your source for the latest updates, announcements, and media coverage about our work and the evolving world of narcolepsy and idiopathic hypersomnia.
Here you’ll find:
We believe in transparency, storytelling, and celebrating progress — even the small wins. Whether we’re featured in an article or launching a new program, this is where you’ll find out what we’re up to.
Putting the Pieces Together, One Story at a Time
Our work is powered by people — and that includes you. If you’re part of the press, a patient advocacy group, or just curious about what we’re building, this is the space to stay connected.
Be sure to check back regularly for updates and follow us on social media for real-time news from the frontlines of narcolepsy and IH advocacy.
News from our partners
12/25/24
HCPlive Sleep Medicine Year in Review: 2024
09/27/24
CENTESSA Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 Agonist, at the 27th Congress of the European Sleep Research Society
09/25/24
AVADEL Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate)
09/03/24
PWN4PWN Welcomes Kyle Chastain as New Treasurer on Board of Directors
07/31/24
AVADEL Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
Older News
06/03/24
TAKEDA Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
02/21/24
Harmony Biosciences U.S. Food and Drug Administration has granted priority review for Harmony Biosciences’ application for WAKIX® (pitolisant) in pediatric narcolepsy
01/24/24
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing
For the Press
Looking to feature PWN4PWN or connect with someone from our board? We’re happy to provide:
